AbbVie Inc. (NYSE:ABBV)

CAPS Rating: 4 out of 5

Results 1 - 20 of 41 : 1 2 3 Next »

Recs

0
Member Avatar racoveanul (80.84) Submitted: 6/28/2015 5:15:24 AM : Outperform Start Price: $68.76 ABBV Score: +1.61

ABBVIE INC, ticker ABBV, has a TTM ROE calculated by Zacks of 177,11%. It's one of my LONG picks.

Recs

0
Member Avatar DrGoldin (99.73) Submitted: 5/16/2015 12:22:36 AM : Outperform Start Price: $63.51 ABBV Score: +10.16

This and BMY are probably the best old-school pharma names right now, but ABBV is a lot cheaper. We're looking at easily 15% annual growth over the next several years (fueled by Humira, Viekira, and of course the shrewd acquisition of Pharmacyclics), and you're only paying 15-16x 2015 earnings for it. So not quite as much growth as Bristol Myers, but not nearly the price, either. Growth at a reasonable price, baby. And I'm not even considering the nice 3% dividend. I'm in at 64.68; I wish I had had the idea ten points ago, but I'm still very comfortable with this entry point.

The only thing I don't like about AbbVie is the dumb name.

Recs

0
Member Avatar Kimer62 (55.02) Submitted: 5/9/2015 8:43:24 AM : Outperform Start Price: $64.74 ABBV Score: +9.40

conservative value play

Recs

0
Member Avatar CellBlock9 (93.18) Submitted: 4/26/2015 11:02:55 AM : Outperform Start Price: $65.54 ABBV Score: +8.72

mgk, 66.07

Recs

0
Member Avatar PuckFan26 (< 20) Submitted: 4/16/2015 9:27:43 PM : Outperform Start Price: $61.97 ABBV Score: +13.36

investment in pharmacyclics will end up paying off in the end and turn into profit. One of the leaders in pharmacyclics is known to make great products and make successful companies

Recs

0
Member Avatar ZenRiDr (57.93) Submitted: 3/2/2015 8:21:06 PM : Outperform Start Price: $59.42 ABBV Score: +19.43

Will have about 15% share if HCV market. Humira.

Recs

0
Member Avatar Dreadnought (57.69) Submitted: 2/28/2015 12:01:12 AM : Outperform Start Price: $59.37 ABBV Score: +19.21

I am going to guess that this company supports Richard Branson and Jeb Bush at the poles. Then again, I might just be thinking about GILD.

Recs

1
Member Avatar bdbcalm (< 20) Submitted: 2/15/2015 4:54:27 PM : Outperform Start Price: $56.16 ABBV Score: +25.89

Sold off due to patent cliff concerns and Hep C drug discounts. I believe this is an overreaction and the stock will recover. There is more in the pipeline than the P/E - 13 - would imply.

Recs

0
Member Avatar Reddog4Sina (48.36) Submitted: 2/5/2015 2:35:07 PM : Outperform Start Price: $57.06 ABBV Score: +21.60

Humira. R+D. Growth. Underappreciated performance.

Recs

3
Member Avatar TMFSpiffyPop (99.58) Submitted: 1/9/2015 1:01:03 PM : Underperform Start Price: $64.20 ABBV Score: -7.03

This mega-cap has made a big run since Express Scripts's announcement that it will take AbbVie's hep C treatment in lieu of Gilead's. Also, an amazing preponderance of CAPS bulls favor this stock beating the market from here -- very interesting. For these reasons (and a couple others, besides), I'm going to thumb this down for the next three years -- a fine company that we can all cheer for, but I'm betting the stock underperforms. I'm emboldened by my Stock Advisor teammate TMFWillSomers who wrote the following for me in an internal research report:

"Although AbbVie has a successful track record and plenty of money to spend or R&D or acquisitions, it faces a huge challenge in filling the sales hole that will open up when Humira comes off patent. Humira is currently the 2nd best-selling drug of all time, and it may even surpass Lipitor as the #1 best-selling drug ever. No easy shoes to fill – especially as biosimilars seem to be making progress. The hep-C treatment will be a multi-billion dollar blockbuster, but it may not be enough."

Brendan gave it a 40% chance to beat the market so I'm siding with my guy. And if he's right, this is partly how you achieve a high CAPS rating -- thumb differently from 99% of others.... Underperform.

Recs

0
Member Avatar gatzbp (91.60) Submitted: 11/14/2014 5:12:45 PM : Underperform Start Price: $62.63 ABBV Score: -9.61

Hep C market is a competitive space with uncertainty on both the asking price (of producers) and the paying price (consumers, medical plans).

Recs

0
Member Avatar manirg (95.63) Submitted: 10/29/2014 3:26:41 PM : Outperform Start Price: $56.06 ABBV Score: +22.84

undervalued

Recs

0
Member Avatar TMFHelical (98.96) Submitted: 10/20/2014 11:24:48 AM : Outperform Start Price: $53.45 ABBV Score: +27.50

Shire aside, AbbVie stands to gain market share in Hep C due to the market's anger at the pricing from Gilead. Approval likely pending.

And if not, there is still Humira, which will be only modestly affected by biosimilars over time.

Recs

0
Member Avatar d3ming (< 20) Submitted: 9/3/2014 5:30:26 PM : Outperform Start Price: $53.70 ABBV Score: +26.84

anti-aging

Recs

0
Member Avatar sjm9 (59.92) Submitted: 8/26/2014 2:05:19 PM : Outperform Start Price: $54.09 ABBV Score: +25.74

Their pipeline includes some some opportunities, including a potential blockbuster hep-C drug.

Recs

0
Member Avatar FloydParks (61.83) Submitted: 8/16/2014 5:56:58 PM : Outperform Start Price: $52.76 ABBV Score: +27.04

Dividends will become increasingly valued in the next few years

Recs

0
Member Avatar cryptelligence (56.76) Submitted: 7/3/2014 6:48:36 PM : Outperform Start Price: $55.75 ABBV Score: +20.39

Algae Play

Recs

1
Member Avatar BaseBawl (< 20) Submitted: 5/29/2014 9:44:04 AM : Outperform Start Price: $52.28 ABBV Score: +25.47

4 more dogs of the dividend aristocrats that I didn't already have. Hudspeth.

Recs

0
Member Avatar ZipMeck (77.12) Submitted: 3/2/2014 11:51:23 AM : Outperform Start Price: $48.03 ABBV Score: +33.22

Have a few in the pipeline coming up in phase 111 and also reviews coming up.

Results 1 - 20 of 41 : 1 2 3 Next »

Featured Broker Partners


Advertisement